Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Gut. 2021 May 31;71(5):938–949. doi: 10.1136/gutjnl-2020-322835

Fig. 6. Functional and clinical significance of EpiC3 and EpiC4 classification.

Fig. 6.

A. Kaplan-Meier plot of survival of CMS2 samples in the TCGA, comparing EpiC4-like patients (n = 37) and EpiC3-like patients (n = 63). The log-rank (Mantel-Cox) p-value is shown for the difference in survival.

B. Pathway analysis for genes in Clusters 2 and 3 from NMF clustering (see Supplementary Fig. S9) of 115 CMS2 TCGA CRC tumors that overlap with EpiC3 and EpiC4-unique genes (LogFC >0.5 and p-value < 0.05). Based on the pathway enrichment, Cluster 2 was annotated as “EpiC4-like” whereas Cluster 3 was annotated as “EpiC3-like”.

C. Violin plots showing protein expression of 4EBP1_pT70, PTEN, p70S6K1, SRC_pY527 and CKIT in EpiC3-like or EpIC4-like TCGA samples.

F. Tumor volume curves for xenografts in NUDE mice generated from transplantation of EpiC3 (left panels, SW948 and SW480) or EpiC4 (right panels, T84 and SW-403) cell lines upon treatment with inhibitors of mTOR (rapamycin, 4mg/kg), SRC/KIT (Dasatinib, 30mg/kg), BRDi (i-BET151, 15mg/kg), or the combination of Rapamycin + iBET-151 or the combination of Dasatinib + iBET-151 or the control vehicle group. Mice were treated every other day. Asterisks show p-values. * <0.05, ** <0.01 and *** <0.001.